ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to address long-term ...
It's not a drug, and it may also have some benefits to quell overeating—here's how tech is transforming mental health care.
WILMINGTON, DE — NRx Pharmaceuticals, Inc. said it has secured Fast Track designation from the U.S. Food and Drug Administration for NRX-100, a preservative-free ketamine formulation aimed at treating ...
Rising clinical innovations, combination therapy advances, and growing cancer prevalence accelerate global and U.S. market growth.Austin, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Keytruda Market Size ...
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...
What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...
The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer (MIBC). The FDA said Friday it has approved ...
Promega has scored an FDA green light for its microsatellite instability testing technology as a companion diagnostic for Merck and Eisai’s Keytruda-Lenvima combination for patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results